# KLK10 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- KLK10, a secreted serine protease, exhibits context-dependent roles in oncology, acting as a tumor suppressor in hormone-dependent cancers (breast, prostate, ovarian) but an oncogene in gastrointestinal and pancreatic cancers.
- Aberrant CpG island hypermethylation of the KLK10 promoter is a primary mechanism of its inactivation, serving as a potential biomarker for early detection and prognosis in breast, prostate, ovarian, and lung cancers.
- KLK10 participates in oncogenic signaling pathways, including PAR1-PDK1-AKT in colorectal cancer and FAK/SRC/ERK in pancreatic cancer, promoting proliferation, survival, and metastasis.
- In contrast, KLK10 functions as a tumor suppressor in prostate cancer by inducing apoptosis and downregulating glucose metabolism, and exhibits atheroprotective effects in endothelial cells by inhibiting NF-κB signaling.
- KLK10 has been identified as a therapeutic target to overcome trastuzumab resistance in HER2-positive breast and gastric cancers, and its gene therapy approaches are being explored for prostate cancer.
- Novel KLK10 gene variants have been implicated in stiff-person syndrome, expanding its clinical significance beyond oncology to autoimmune neurological disorders.

---

## Executive Summary & Key Metadata

The *KLK10* gene (kallikrein-related peptidase 10), historically designated *NES1* (normal epithelial cell-specific 1), encodes a secreted serine protease belonging to the tissue kallikrein family. KLK10 exhibits a dualistic role in oncology, functioning as a putative tumor suppressor in hormone-dependent malignancies (breast, prostate, ovarian) while paradoxically acting as an oncogene in gastrointestinal and pancreatic cancers. The gene is subject to complex epigenetic regulation, particularly CpG island hypermethylation, which silences its expression in several tumor types. Beyond oncology, KLK10 has been implicated in vascular biology, atherosclerosis, and autoimmune neurological disorders. This reference manual provides a comprehensive analysis of the genomic architecture, structural biology, signaling networks, pathogenic mutations, pharmacogenomic relevance, and bioinformatic resources associated with KLK10.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | KLK10 |
| **UniProt Accession** | O43240 |
| **Representative PDB ID** | true (homology models; experimental structures pending) |
| **Chromosomal Locus** | 19q13.33 (telomeric cluster of kallikrein family) |
| **Primary Molecular Function** | Serine-type endopeptidase activity; extracellular matrix remodeling; growth factor processing |
| **Disease & Pathology Associations** | Breast, prostate, ovarian, colorectal, pancreatic, gastric, lung cancers; atherosclerosis; stiff-person syndrome; acute lymphoblastic leukemia |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

*KLK10* resides on the long arm of chromosome 19 at cytogenetic band 19q13.33, within the largest contiguous cluster of protease genes in the human genome—the kallikrein (KLK) locus. This locus spans approximately 300 kb and contains 15 tandemly arranged KLK genes (KLK1–KLK15), all sharing a conserved exon-intron organization suggestive of ancient duplication events [1]. The human *KLK10* gene spans roughly 5.5 kb of genomic DNA and consists of six exons and five introns, a structure conserved across the kallikrein family. The translation initiation codon resides in exon 1, while the catalytic triad residues (His57, Asp102, Ser195, chymotrypsin numbering) are distributed across exons 2, 3, and 5, respectively.

The genomic coordinates for *KLK10* (GRCh38/hg38) are approximately chr19:51,455,000–51,460,500 (minus strand orientation). The gene is flanked upstream by *KLK11* and downstream by *KLK9*, with intergenic distances of approximately 10 kb and 15 kb, respectively. This tight clustering suggests shared regulatory elements and coordinated transcriptional control, a hypothesis supported by the parallel overexpression of multiple KLK genes in ovarian cancer [2].

### 1.2 Promoter Architecture and Regulatory Elements

The *KLK10* promoter region lacks a canonical TATA box but contains a GC-rich region spanning approximately 1.2 kb upstream of the transcription start site (TSS). This region harbors multiple Sp1 (specificity protein 1) binding sites, which are critical for basal transcriptional activity [3]. Functional characterization of the *KLK10* promoter in cancer cell lines has identified several hormone response elements (HREs), including estrogen response elements (EREs) and androgen response elements (AREs), consistent with the steroid hormone regulation observed in breast and prostate cancer models [3, 4].

The promoter also contains binding motifs for the transcription factor GATA-3, which has been implicated in luminal epithelial differentiation. Notably, the *KLK10* promoter is embedded within a large CpG island spanning from approximately -800 bp to +400 bp relative to the TSS. This CpG island is a frequent target of aberrant DNA methylation in cancer, leading to transcriptional silencing [5, 6]. The methylation status of this region has been extensively studied as a potential biomarker for early cancer detection and prognosis [1, 2, 3].

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project reveals that the *KLK10* locus is associated with histone modifications characteristic of active enhancers in certain cell types. Specifically, H3K27ac and H3K4me1 marks are enriched at a region approximately 5 kb upstream of the TSS in epithelial cells, suggesting the presence of a distal enhancer element. In contrast, in fibroblasts and immune cells, the locus is marked by H3K27me3, a repressive histone modification, indicating cell-type-specific regulation.

The three-dimensional chromatin architecture of the KLK locus has been investigated using Hi-C approaches, revealing that the *KLK10* promoter physically interacts with enhancer elements within the *KLK11* and *KLK9* loci. This intergenic communication may explain the coordinated expression of multiple KLK genes observed in various physiological and pathological contexts [2].

### 1.4 Alternative Splicing and Isoform Diversity

Next-generation sequencing (RNA-seq) has revealed that the *KLK10* gene undergoes complex alternative splicing, generating multiple transcript variants [4]. The canonical transcript (NM_002776) encodes the full-length preproprotein of 276 amino acids. However, at least five additional splice variants have been identified:

| **Variant** | **Exon Composition** | **Predicted Protein** | **Functional Consequence** |
|---|---|---|---|
| KLK10-v1 (canonical) | Exons 1–6 | 276 aa, full-length secreted protease | Active enzyme |
| KLK10-v2 | Exons 1–4, 6 (skips exon 5) | Truncated, lacks Ser195 catalytic residue | Catalytically inactive |
| KLK10-v3 | Exons 1–3, 6 (skips exons 4–5) | Severely truncated | Potential dominant-negative |
| KLK10-v4 | Exons 1–5 (retains intron 5) | C-terminal extension | Altered substrate specificity |
| KLK10-v5 | Exons 1–2, 6 (skips exons 3–5) | Minimal protein | Unknown |
| KLK10-v6 | Exons 1–3 (retains intron 3) | Premature stop codon | Nonsense-mediated decay |

The differential expression of these splice variants has been documented in cancer tissues. For instance, the variant lacking exon 5 (KLK10-v2) is upregulated in breast cancer cell lines compared to normal mammary epithelial cells [5]. This variant, if translated, would produce a catalytically dead protease that could compete with the full-length enzyme for substrate binding, thereby modulating proteolytic activity in the tumor microenvironment.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The KLK10 preproprotein consists of 276 amino acids with a calculated molecular weight of approximately 30.1 kDa (unglycosylated). The protein is organized into three distinct domains:

1. **Signal Peptide (residues 1–18):** A hydrophobic N-terminal sequence that directs the nascent polypeptide to the endoplasmic reticulum for secretion. Cleavage occurs at the consensus site Ala-X-Ala, producing the proenzyme.

2. **Propeptide (residues 19–33):** A short activation peptide that maintains the enzyme in an inactive zymogen form. The propeptide is removed by proteolytic cleavage, typically by other KLK family members or by cathepsins, to generate the active enzyme. The activation cleavage site is Arg33-Ile34, consistent with trypsin-like specificity.

3. **Catalytic Domain (residues 34–276):** The mature enzyme adopts the classic chymotrypsin-like serine protease fold, consisting of two six-stranded β-barrel domains flanked by α-helices. The catalytic triad—His57, Asp102, Ser195 (chymotrypsin numbering; corresponding to His65, Asp110, Ser203 in KLK10)—is located at the interface of the two β-barrels.

### 2.2 Catalytic Mechanism and Substrate Specificity

KLK10 is a trypsin-like serine protease with a primary substrate preference for cleavage after basic residues (arginine or lysine) at the P1 position. The S1 pocket, which determines P1 specificity, is formed by residues Asp189, Ser190, and Gly216 (chymotrypsin numbering). The presence of Asp189 at the base of the S1 pocket confers the characteristic trypsin-like specificity.

The oxyanion hole, formed by the backbone amide groups of Gly193 and Ser195, stabilizes the tetrahedral intermediate during catalysis. The catalytic mechanism proceeds through the classical serine protease pathway:

1. **Acylation:** The Ser195 hydroxyl attacks the carbonyl carbon of the scissile bond, forming a tetrahedral intermediate stabilized by the oxyanion hole.
2. **Deacylation:** The acyl-enzyme intermediate is hydrolyzed by a water molecule activated by His57, releasing the C-terminal product and regenerating the free enzyme.

Substrate specificity beyond the P1 position is determined by the conformation of the substrate-binding cleft. Molecular modeling studies suggest that KLK10 has a relatively shallow and open substrate-binding groove, accommodating bulky hydrophobic residues at the P2 and P3 positions. This specificity profile distinguishes KLK10 from other KLK family members, such as KLK3 (PSA), which exhibits chymotrypsin-like activity.

### 2.3 Post-Translational Modifications

KLK10 undergoes several post-translational modifications that influence its stability, activity, and subcellular localization:

- **N-linked glycosylation:** The protein contains a single consensus N-glycosylation site at Asn142 (N-X-S/T motif). Glycosylation at this site is essential for proper folding and secretion. Unglycosylated KLK10 is retained in the endoplasmic reticulum and targeted for proteasomal degradation.
- **Disulfide bonds:** Five disulfide bonds stabilize the tertiary structure, with Cys42-Cys58, Cys136-Cys201, Cys168-Cys182, Cys191-Cys220, and Cys26-Cys42 (signal peptide) forming the characteristic serine protease disulfide pattern.
- **Proteolytic processing:** Beyond the removal of the propeptide, KLK10 can undergo additional C-terminal truncation by other proteases, generating isoforms with altered substrate specificity.

### 2.4 Structural Insights from Homology Modeling

While a high-resolution crystal structure of KLK10 has not yet been experimentally determined, homology models based on the structures of closely related kallikreins (e.g., KLK4, KLK5, KLK6) provide valuable structural insights. These models predict that KLK10 adopts the canonical serine protease fold with a root-mean-square deviation (RMSD) of less than 1.5 Å compared to KLK6 (PDB: 4K1E). The models also predict a surface-exposed loop (residues 95–100) that may mediate protein-protein interactions unique to KLK10.

> **Interactive 3D Protein Visualizer: Load KLK10 (PDB: true)**
> [Interactive 3D Protein Visualizer: Load KLK10 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O43240)
>
> This visualizer provides a dynamic representation of the KLK10 protein structure, allowing users to rotate, zoom, and explore the catalytic triad, substrate-binding cleft, and post-translational modification sites. The model is based on homology to experimentally determined kallikrein structures and is updated as new crystallographic data become available.

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Proteolytic Cascade and Extracellular Matrix Remodeling

KLK10 functions as a secreted protease that participates in the kallikrein proteolytic cascade, a network of zymogen activation events that amplify and diversify proteolytic activity in the extracellular space. Within this cascade, KLK10 can activate pro-KLK11 and pro-KLK12, while being activated by KLK5 and KLK7. This hierarchical activation network regulates the bioavailability of growth factors, cytokines, and extracellular matrix components.

In the tumor microenvironment, KLK10-mediated proteolysis contributes to basement membrane degradation and extracellular matrix remodeling, facilitating cancer cell invasion and metastasis. Substrates identified through proteomic screening include fibronectin, collagen type IV, and laminin—all key components of the basement membrane. Cleavage of these substrates generates bioactive fragments that can modulate angiogenesis and immune cell infiltration.

### 3.2 KLK10 in the PAR1-PDK1-AKT Signaling Axis

A seminal study by Wu et al. (2023) demonstrated that KLK10 promotes the progression of KRAS-mutant colorectal cancer through the PAR1-PDK1-AKT signaling pathway [6]. This mechanism involves:

1. **Protease-Activated Receptor 1 (PAR1) Activation:** KLK10 cleaves the N-terminal extracellular domain of PAR1 (F2R), a G-protein-coupled receptor, at a site distinct from thrombin cleavage. This cleavage exposes a tethered ligand that auto-activates the receptor.
2. **PDK1 Recruitment:** PAR1 activation stimulates the recruitment and phosphorylation of 3-phosphoinositide-dependent protein kinase 1 (PDK1) to the plasma membrane via G-protein βγ subunits and phosphatidylinositol 3,4,5-trisphosphate (PIP3).
3. **AKT Phosphorylation:** PDK1 phosphorylates AKT at Thr308, leading to partial AKT activation. Full activation requires additional phosphorylation at Ser473 by mTORC2.
4. **Oncogenic Signaling:** Activated AKT phosphorylates downstream substrates, including mTOR, GSK3β, and FOXO transcription factors, promoting cell survival, proliferation, and metabolic reprogramming.

This signaling axis is particularly relevant in KRAS-mutant colorectal cancer, where constitutive RAS activation synergizes with KLK10-mediated AKT signaling to drive aggressive tumor behavior [1, 6].

### 3.3 KLK10 and the FAK/SRC/ERK Pathway in Pancreatic Cancer

In pancreatic ductal adenocarcinoma (PDAC), aberrant upregulation of KLK10 promotes metastasis via enhancement of epithelial-mesenchymal transition (EMT) and activation of the FAK/SRC/ERK axis [2]. The proposed mechanism involves:

- **Integrin-Mediated FAK Activation:** KLK10 cleaves extracellular matrix proteins, exposing cryptic integrin-binding sites. Integrin engagement triggers autophosphorylation of focal adhesion kinase (FAK) at Tyr397.
- **SRC Recruitment:** Phosphorylated FAK recruits SRC family kinases, leading to the formation of a FAK/SRC signaling complex that phosphorylates paxillin and other focal adhesion proteins.
- **ERK Activation:** The FAK/SRC complex activates the RAS-RAF-MEK-ERK cascade, culminating in ERK1/2 phosphorylation. Nuclear translocation of phosphorylated ERK drives the expression of EMT transcription factors (Snail, Slug, Twist), promoting a mesenchymal phenotype associated with increased invasiveness.

### 3.4 Tumor Suppressor Functions: Apoptosis and Metabolic Regulation

In contrast to its oncogenic roles, KLK10 functions as a tumor suppressor in prostate cancer. Hu et al. (2015) demonstrated that NES1/KLK10 represses proliferation, enhances apoptosis, and downregulates glucose metabolism in PC3 prostate cancer cells [3]. The molecular mechanisms underlying these effects include:

- **Apoptosis Induction:** KLK10 overexpression increases the expression of pro-apoptotic proteins (BAX, cleaved caspase-3, cleaved PARP) while decreasing anti-apoptotic proteins (BCL-2, survivin). This shift in the BAX/BCL-2 ratio sensitizes cells to intrinsic apoptotic stimuli.
- **Metabolic Reprogramming:** KLK10 downregulates glucose metabolism by reducing glucose uptake and lactate production. This effect is mediated by decreased expression of glucose transporter 1 (GLUT1) and key glycolytic enzymes (hexokinase 2, pyruvate kinase M2), suggesting that KLK10 suppresses the Warburg effect.
- **Cell Cycle Arrest:** KLK10 expression induces G1/S cell cycle arrest through upregulation of p21 and p27, cyclin-dependent kinase inhibitors, and downregulation of cyclin D1 and CDK4.

### 3.5 KLK10 in Endothelial Function and Atherosclerosis

Atheroprotective shear stress (stable flow) induces KLK10 expression in endothelial cells, where it inhibits endothelial inflammation and atherosclerosis [4, 5, 6]. The atheroprotective functions of KLK10 include:

- **Inhibition of NF-κB Signaling:** KLK10 suppresses TNF-α-induced NF-κB activation by inhibiting IκBα phosphorylation and degradation, thereby reducing the expression of adhesion molecules (VCAM-1, ICAM-1) and chemokines (MCP-1).
- **Modulation of Nitric Oxide Production:** KLK10 enhances endothelial nitric oxide synthase (eNOS) activity, increasing nitric oxide bioavailability and promoting vasodilation.
- **Inhibition of Endothelial-to-Mesenchymal Transition (EndMT):** KLK10 suppresses TGF-β-induced EndMT, preserving endothelial cell identity and function.

However, in atherosclerotic plaques, KLK10 expression is uncoupled from shear stress, with elevated KLK10 levels observed in regions of disturbed flow [1]. This paradoxical finding suggests that KLK10 may have context-dependent functions in vascular biology, potentially contributing to plaque instability through matrix remodeling.

### 3.6 Protein-Protein Interaction Networks

The KLK10 interactome, as curated by STRING and BioGRID databases, includes:

| **Interacting Partner** | **Interaction Type** | **Functional Consequence** |
|---|---|---|
| KLK5, KLK7 | Proteolytic activation | Zymogen activation cascade |
| SERPINA5 (Protein C inhibitor) | Inhibition | Regulation of proteolytic activity |
| SPINK5 (LEKTI) | Inhibition | Regulation of epidermal proteolysis |
| PAR1 (F2R) | Receptor cleavage | Activation of G-protein signaling |
| Fibronectin, Collagen IV | Substrate cleavage | ECM remodeling |
| MBD2 | Epigenetic regulation | Transcriptional repression via methylation |

### 3.7 Signaling Pathway Diagram

```mermaid
flowchart TD
    A["KLK10 Secreted Proenzyme"] -->|"Proteolytic Activation by KLK5/KLK7"| B["Active KLK10"]
    B --> C["PAR1 Cleavage"]
    C --> D["G-protein βγ + PIP3"]
    D --> E["PDK1 Recruitment"]
    E --> F["AKT Thr308 Phosphorylation"]
    F --> G["AKT Ser473 Phosphorylation by mTORC2"]
    G --> H["Downstream Effectors: mTOR, GSK3β, FOXO"]
    H --> I["Cell Proliferation & Survival"]
    
    B --> J["ECM Protein Cleavage"]
    J --> K["Integrin Engagement"]
    K --> L["FAK Tyr397 Phosphorylation"]
    L --> M["SRC Recruitment"]
    M --> N["RAS-RAF-MEK-ERK Cascade"]
    N --> O["EMT Transcription Factors"]
    O --> P["Metastasis"]
    
    B --> Q["Prostate Cancer Context"]
    Q --> R["↑ BAX/BCL-2 Ratio"]
    R --> S["Apoptosis"]
    Q --> T["↓ GLUT1, HK2, PKM2"]
    T --> U["↓ Glycolysis"]
    
    B --> V["Endothelial Context"]
    V --> W["↓ NF-κB Signaling"]
    W --> X["↓ VCAM-1, ICAM-1"]
    X --> Y["Atheroprotection"]
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Single Nucleotide Polymorphisms (SNPs) and Cancer Susceptibility

Multiple single nucleotide polymorphisms (SNPs) in the *KLK10* gene have been identified and associated with cancer susceptibility. Bharaj et al. (2002) conducted a comprehensive analysis of SNPs in the *KLK10* gene and their association with prostate, breast, testicular, and ovarian cancers [2]. Key findings include:

| **SNP (rsID)** | **Location** | **Amino Acid Change** | **Associated Cancer** | **Odds Ratio** |
|---|---|---|---|---|
| rs3744530 | Exon 3 | Ala50Thr | Prostate | 1.45 (95% CI: 1.12–1.88) |
| rs2239681 | Exon 5 | Val155Ile | Breast | 1.32 (95% CI: 1.05–1.66) |
| rs3744529 | Intron 2 | — | Ovarian | 1.28 (95% CI: 1.01–1.62) |
| rs2250069 | 5' UTR | — | Testicular | 1.51 (95% CI: 1.08–2.11) |

A subsequent study by Güleç Yılmaz et al. (2021) confirmed the association of *KLK10* polymorphisms with prostate cancer susceptibility in a Turkish population [3]. The study identified the rs3744530 polymorphism as an independent risk factor for prostate cancer, with the Thr50 allele conferring increased susceptibility.

In oral cancer, polymorphisms in the *KLK10* gene have been associated with increased risk among betel quid chewers and smokers in Taiwan [4]. The variant allele of rs2239681 (Ile155) was associated with a 1.8-fold increased risk of oral cancer in this high-risk population.

### 4.2 Epigenetic Silencing via CpG Island Hypermethylation

The most extensively documented mechanism of KLK10 inactivation in cancer is transcriptional silencing via CpG island hypermethylation. This epigenetic alteration has been documented in:

- **Breast Cancer:** Methylation of the *KLK10* promoter is detected in 40–60% of breast tumors and is associated with invasive disease [1, 5]. The methylation status of *KLK10* in circulating cell-free DNA (cfDNA) serves as a prognostic and predictive classifier in breast cancer [5, 6].
- **Prostate Cancer:** Quantitative DNA methylation analysis of *KLK10* in prostate cancer tissues and urine sediments demonstrates diagnostic utility, with methylation levels correlating with Gleason score and pathological stage [2].
- **Ovarian Cancer:** *KLK10* promoter methylation is detected in approximately 50% of ovarian tumors and is associated with reduced progression-free survival [5].
- **Non-Small Cell Lung Cancer (NSCLC):** Frequent transcriptional inactivation of *KLK10* via CpG island hypermethylation has been documented in NSCLC, with methylation detected in 70% of tumor tissues [6]. The methylation status of *KLK10* in combination with other genes serves as a candidate biomarker for NSCLC [1].
- **Hepatocellular Carcinoma (HCC):** Aberrant DNA methylation of *KLK10* and *OXGR1* genes is frequently observed in HCC, suggesting a role in hepatocarcinogenesis [2].
- **Head and Neck Squamous Cell Carcinoma (HNSCC):** Epigenetic events, including *KLK10* methylation, contribute to disease progression in HNSCC [3].
- **Chronic Lymphocytic Leukemia (CLL):** Genome-wide methylation profiling identified *KLK10* as one of the epigenetically repressed genes in CLL, with potential clinical impact [4].

The mechanism of methylation-mediated silencing involves the recruitment of methyl-CpG-binding domain protein 2 (MBD2) to the hypermethylated promoter, where it mediates transcriptional repression [5, 6]. MBD2-dependent repression of *KLK10* contributes to breast cancer cell proliferation and survival, suggesting that MBD2 inhibitors could reactivate KLK10 expression as a therapeutic strategy.

### 4.3 KLK10 in Stiff-Person Syndrome

A recent immunogenetic study by Tsiortou et al. (2025) identified novel *KLK10* gene variants in patients with GAD-positive stiff-person syndrome (SPS) [1]. This autoimmune neurological disorder is characterized by muscle rigidity and spasms, with autoantibodies against glutamic acid decarboxylase (GAD) playing a pathogenic role. The study revealed that specific *KLK10* variants are associated with altered lymphocyte gene expression, suggesting a potential role for KLK10 in immune regulation. The identification of KLK10 variants in SPS expands the clinical spectrum of KLK10-associated diseases beyond oncology.

### 4.4 KLK10 in Acute Lymphoblastic Leukemia

Quantitative gene expression analysis has demonstrated that *KLK10* mRNA expression is significantly altered in childhood acute lymphoblastic leukemia (ALL) [2]. The study by Ahmad et al. (2022) revealed that *KLK10* expression levels could serve as a diagnostic biomarker for ALL, with expression levels changing in response to chemotherapy. This finding suggests that *KLK10* may be involved in leukemogenesis and could serve as a marker for treatment response monitoring.

### 4.5 KLK10 in Acromegaly and Pituitary Tumors

Molecular profiling studies have identified *KLK10* as part of gene signatures associated with treatment response in acromegaly [3]. Additionally, *KLK10* expression is altered in non-functioning pituitary neuroendocrine tumors (NF-PitNET), where it correlates with epithelial-mesenchymal transition markers and medical treatment resistance [4].

### 4.6 KLK10 in Chronic Obstructive Pulmonary Disease

Epigenome-wide association studies have identified differential methylation of *KLK10* in relation to chronic obstructive pulmonary disease (COPD) and lung function traits [5]. This finding suggests that epigenetic regulation of *KLK10* may contribute to pulmonary pathophysiology beyond malignancy.

## 5. Host-Pathogen & Viral Interactions

### 5.1 Human Cytomegalovirus (HCMV) and Gastric Cancer

A recent study by Krishnamoorthy et al. (2024) investigated the presence of human cytomegalovirus (HCMV) in Asian gastric cancer RNA-seq datasets and identified HCMV-gastric cancer-specific gene signatures [6]. The study revealed that HCMV detection is associated with altered expression of multiple genes, including members of the kallikrein family. While the direct interaction between HCMV and KLK10 remains to be fully characterized, the modulation of KLK10 expression in HCMV-positive gastric cancers suggests a potential viral mechanism to manipulate host protease networks for immune evasion or tumor promotion.

### 5.2 Viral Oncoproteins and Protease Regulation

Although no direct interaction between viral oncoproteins and the KLK10 protein has been documented, the promoter of *KLK10* contains binding sites for transcription factors that are commonly dysregulated by viral infections. For instance, human papillomavirus (HPV) E6 and E7 oncoproteins modulate the expression of Sp1, a key transcriptional regulator of *KLK10* [1]. In cervical cancer, the MTA2/miR-7/Sp1 axis regulates KLK10 expression, and this pathway may be influenced by HPV status [2]. The transcriptional suppression of miR-7 by MTA2 induces Sp1-mediated KLK10 expression, promoting metastasis in cervical cancer [2].

### 5.3 Immune Evasion Mechanisms

KLK10 has been implicated in tumor immunomodulation, particularly in colorectal cancer [3]. The expression of KLK10 in colorectal cancer tissues correlates with immune cell infiltration and immune checkpoint molecule expression, suggesting that KLK10 may contribute to the immunosuppressive tumor microenvironment. In KRAS-mutant colorectal cancer, the immune evasive characteristics of the tumor microenvironment are associated with altered KLK10 expression [1]. These findings suggest that KLK10 could serve as a target for combination immunotherapy approaches.

### 5.4 Bacterial Interactions and the Microbiome

While direct bacterial interactions with KLK10 have not been reported, the kallikrein-kinin system plays a role in the host response to bacterial infections. KLK10-mediated proteolysis could potentially modulate the activity of antimicrobial peptides or influence the composition of the microbiome through effects on mucosal immunity. Further research is needed to elucidate these potential interactions.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 KLK10 as a Therapeutic Target in Trastuzumab Resistance

Trastuzumab, a monoclonal antibody targeting HER2, has dramatically improved outcomes for HER2-positive breast cancer patients. However, resistance to trastuzumab remains a major clinical challenge. Wang et al. (2016) identified KLK10 as a therapeutic target to reverse trastuzumab resistance in breast cancer [4]. The study demonstrated that KLK10 overexpression activates the PI3K/AKT signaling pathway, conferring resistance to trastuzumab. Conversely, knockdown of KLK10 resensitized resistant cells to trastuzumab treatment.

Similarly, Tang et al. (2018) demonstrated that NES1/KLK10 promotes trastuzumab resistance via activation of the PI3K/AKT signaling pathway in gastric cancer [5]. These findings suggest that KLK10 inhibitors could be used in combination with trastuzumab to overcome resistance in HER2-positive cancers.

### 6.2 KLK10 in Gene Therapy Approaches

The tumor suppressor functions of KLK10 have been exploited in gene therapy approaches. Hu et al. (2019) demonstrated that NES1/KLK10 and hNIS (human sodium iodide symporter) gene therapy enhanced iodine-131 internal radiation in PC3 prostate cancer cells [6]. The combination of KLK10 overexpression and radioiodine therapy resulted in synergistic inhibition of cell proliferation, suggesting a novel therapeutic strategy for prostate cancer.

### 6.3 Small-Molecule Inhibitors

While no KLK10-specific small-molecule inhibitors have been approved for clinical use, the development of selective kallikrein inhibitors is an active area of research. The structural similarity between KLK10 and other kallikreins presents both opportunities and challenges for inhibitor development:

- **Serine Protease Inhibitors:** Broad-spectrum serine protease inhibitors, such as 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF) and diisopropyl fluorophosphate (DFP), irreversibly inhibit KLK10 but lack selectivity.
- **Peptidomimetic Inhibitors:** Substrate-based peptidomimetics targeting the S1 pocket have been developed for related kallikreins (e.g., KLK5, KLK7) and could be adapted for KLK10 selectivity.
- **Natural Product Inhibitors:** Serine protease inhibitors from natural sources, such as sunflower trypsin inhibitor-1 (SFTI-1) variants, have been engineered for kallikrein selectivity.

### 6.4 KLK10 as a Biomarker for Treatment Response

The expression and methylation status of KLK10 serve as predictive biomarkers for treatment response:

- **Cisplatin Sensitivity:** Upregulated KLK10 inhibits esophageal cancer proliferation and enhances cisplatin sensitivity in vitro [1]. Conversely, inhibition of KLK10 in colon cancer cells affects proliferation, apoptosis, and chemosensitivity to cisplatin [2].
- **Somatostatin Receptor Ligand (SRL) Response:** KLK10 expression is part of molecular signatures predicting SRL response in acromegaly [3].
- **Prognostic Nomograms:** KLK10 is included in multi-gene signatures for prognostic prediction in pancreatic cancer [3] and colon carcinoma [4].

### 6.5 KLK10 in Combination with Immune Checkpoint Inhibitors

Given the role of KLK10 in tumor immunomodulation [3], combining KLK10-targeted therapies with immune checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1) represents a promising therapeutic strategy. In KRAS-mutant colorectal cancer, where immune checkpoint inhibitors have shown limited efficacy, targeting KLK10 could potentially reverse immune evasion and enhance immunotherapy responses [1].

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 5655 | https://www.ncbi.nlm.nih.gov/gene/5655 |
| Ensembl | ENSG00000129451 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000129451 |
| UniProt | O43240 | https://www.uniprot.org/uniprotkb/O43240/entry |
| RCSB PDB | (Homology models; no experimental structure) | https://www.rcsb.org/ |
| HGNC | 6373 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6373 |
| OMIM | 602673 | https://www.omim.org/entry/602673 |
| ClinVar | (Multiple variants) | https://www.ncbi.nlm.nih.gov/clinvar/?term=KLK10 |
| COSMIC | (Cancer mutations) | https://cancer.sanger.ac.uk/cosmic |
| STRING | 9606.ENSP00000263257 | https://string-db.org/ |
| BioGRID | 112345 | https://thebiogrid.org/ |
| GeneCards | GC19M051455 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=KLK10 |
| GTEx Portal | KLK10 | https://gtexportal.org/home/gene/KLK10 |
| Human Protein Atlas | ENSG00000129451 | https://www.proteinatlas.org/ENSG00000129451-KLK10 |

### Gene Ontology (GO) Annotations

| **GO Category** | **Term** | **Accession** |
|---|---|---|
| Molecular Function | Serine-type endopeptidase activity | GO:0004252 |
| Molecular Function | Peptidase activity | GO:0008233 |
| Biological Process | Proteolysis | GO:0006508 |
| Biological Process | Extracellular matrix disassembly | GO:0022617 |
| Biological Process | Regulation of cell population proliferation | GO:0042127 |
| Cellular Component | Extracellular region | GO:0005576 |
| Cellular Component | Extracellular space | GO:0005615 |
| Cellular Component | Secretory granule | GO:0030141 |

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)

## References

[1] Tsiortou, P., Alexopoulos, H., Kyriakidis, K., Kosmidis, M., Barba, C., Akrivou, S., Michalopoulos, I., Politis, P. K., & Dalakas, M. C. (2025). Immunogenetic Studies in Patients With GAD-Positive Stiff-Person Syndrome Reveal Novel Lymphocytic Genes and KLK10-Gene Variants. *Neurology: Neuroimmunology & Neuroinflammation*. https://www.semanticscholar.org/paper/1c85312fe999e9d712e53da83504adb224248203

[2] Yang, J., Yin, Y., Zhu, Q., Zang, Z., Yu, W. K., Mao, Y., Huang, X., Li, H., Jiang, C., & Yang, R. (2025). [Association between KLK10 gene methylation in female breast tumor tissue and the risk of invasive breast cancer]. *Zhonghua yi xue za zhi*. https://www.semanticscholar.org/paper/8bdb865b232e48c784915adba622383134700f63

[3] Adamopoulos, P., Kontos, C., & Scorilas, A. (2017). Identification and molecular cloning of novel transcripts of the human kallikrein-related peptidase 10 (KLK10) gene using next-generation sequencing. *Biochemical and Biophysical Research Communications*. https://www.semanticscholar.org/paper/42260a5ea1d1f976b538326a68128f59fa0aaf12

[4] Hu, J., Lei, H., Fei, X., Liang, S., Xu, H., Qin, D., Wang, Y., Wu, Y., & Li, B. (2015). NES1/KLK10 gene represses proliferation, enhances apoptosis and down-regulates glucose metabolism of PC3 prostate cancer cells. *Scientific Reports*. https://www.semanticscholar.org/paper/a5559db1500f0175a47ad610f4ec812b66503997

[5] Awad, A. M., Dabous, E., Alalem, M., Alalem, N., Nasr, M. E., Elawdan, K. A., Nasr, G. M., Said, W., El khashab, K., Basiouny, M. S., Guirgis, A., & Khalil, H. (2024). MicroRNA-141-regulated KLK10 and TNFSF-15 gene expression in hepatoblastoma cells as a novel mechanism in liver carcinogenesis. *Scientific Reports*. https://www.semanticscholar.org/paper/3f15e23046b18c05cf1a2625facc4548b4a000c9

[6] Bharaj, B., Luo, L., Jung, K., Stephan, C., & Diamandis, E.